Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"